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conservative surgery after partial breast irradiation (PBI) for primary 
tumor 
Materials and Methods: Patients with local recurrence in quadrants 
other than the previous one treated with full dose intraoperative 
electrons (ELIOT), who received a second breast conservative surgery, 
are enrolled in this ongoing phase I/II study called POLO ( Partially 
Omitted LObe). The primary endpoint is acute toxicity. The area 
previously irradiated with PBI is identified through surgical clips, 
inserted at the time of first quadrantectomy. The treatment volume 
comprise the whole breast minus the part previously irradiated with 
PBI. The whole breast and the recurrent tumor bed are planned to 
receive a dose of 45 Gy and 50 Gy , respectively, in 20 fractions, 
5d/wk within 4 weeks. According to the protocol, 5%, 25% 50% and 
95% of the area ELIOT should not receive more than 20Gy, 15 Gy, 10 
Gy and 5 Gy, respectively. Treatment plans are generated using 
helical tomotherapy (Tomotherapy Inc., Madison, WI) 
Results:  
  
So far, 3 patients entered the study. The mean age was 59 years. The 
histology at time of recurrence was invasive and the mean tumor size 
was 0.6 mm. All patients had quadrantectomy with negative margins 
and sentinel node biopsy. The mean time between initial radiotherapy 
and reirradiation was 100 months. All patients had been given PBI with 
21 Gy -full dose intraoperative electrons. The salvage radiotherapy 
comprises whole breast irradiation minus PBI area: by exploiting 
helical tomotherapy , a well-demarcated cold area of underdosage in 
the previously irradiated ELIOT area is created (Fig.1). The following 
treatment plan parameters are given as mean values. The 5%, 25%, 
50% and 95% of the volume of the previously ELIOT area were given 
21.6 Gy, 13.8 Gy, 8.8 Gy, 3.6 Gy respectively. Regarding the whole 
breast, V95% and V90% were 88.1% and 95.4%, respectively , Dmax was 
113.5 % ( with V 107% being 1,25 %) and Dmean were 99.5%. Proper 
DVH constraints and penalities are applied to improve target coverage 
while minimizing the previously irradiated area. Acute toxicity was 
excellent. During treatment the maximum RTOG grade was G2 
erithema (1 patient) and G2 patchy desquamation ( 1 patient) , not 
involving the ELIOT region. One month after, no side effects were 
recorded. 
Conclusions: Given the increased numbers of patients treated with 
conservative surgery and partial breast irradiation, the management 
of tumor reappearances in the untreated remaining breast is bound to 
be a matter of controversy. The technical feasibility of retreatment of 
the whole breast while sparing the primary tumor bed region 
previously irradiated with a PBI modality is a step to investigate.  
   
PO-0688   
RapidArcTM for breast and nodal irradiation: a solution for patients 
with challenging complex anatomy 
O. Riou1, G. Baumont2, C. Lemanski1, M. Charissoux1, C. Llacer 
Moscardo1, O. Lauche1, N. Aillères1, J.B. Dubois1, D. Azria1, P. 
Fenoglietto1 
1CRLC Val d'Aurelle/Paul Lamarque, Radiation Oncology, Montpellier 
Cedex 5, France  
2Ste Clotilde Clinic, Radiation Oncology, La Réunion, France  
 
Purpose/Objective: The advantage of Intensity Modulated 
Radiotherapy over tridimensional conformal radiotherapy (3D-CRT) for 
breast cancer remains controversial. However, target volume 
coverage and healthy tissue protection are not adequate with 3D-CRT 
under certain complex anatomical conditions. We present here the 
dosimetric results of the first patients treated with volumetric 
modulated arctherapy (VMAT) at our institution. 
Materials and Methods: Nine patients whose PTV coverage was 
unsatisfactory with 3D-CRT were selected. They were all replanned 
and treated with VMAT. A 7 mm extension was used to create the 
PTVs from the breast and lymph nodes CTVs, excluding the first 5 mm 
under the skin. Radiation was delivered by using two 6 MV photons 
partial arcs of 240°. The prescribed doses were 52.2 Gy to the breast 
and lymph nodes and 63.2 Gy to the tumor bed in 29 fractions, using 
the integrated boost method. Dosimetric results regarding PTV 
coverage and normal tissues protection (including contralateral 
breast, ipsilateral and contralateral lungs and heart) were collected. 
Results: On average, 90% and 95% of the breast PTV received 
respectively 97.2 % [93.2 -99, 9] and 91.7 % [80.6 - 98.2] of the 
prescribed dose. Ninety % and 95 % of the supraclavicular PTV 
received respectively 94.6 % [84 - 100] and 88.5 % [72-98] of the 
prescribed dose. For internal mammary chain volume, 90 % and 95 % 
of the PTV received respectively 96.4 % [87 - 100] and 90 % [75 - 100] 
of the prescribed dose. For ipsilateral lung, the volume receiving 5 Gy 
(V5) was 90 % [75-100], the volume receiving 20 Gy (V20) was 23.6% 
[13.7 - 35] and the volume receiving 30 Gy (V30) was 9.7% [4.7 - 14]. 
The average ipsilateral lung dose was 15 Gy [11-19]. For the 
contralateral lung, V5 was 38.9 % [16.6 to 68.5], V10 was 5.4 % [0-15] 
and the average dose was 5 Gy [3.4 to 7.2]. For the heart, V5 was 78.1 
% [49 - 100] and V35 was 0.8 % [0 -5]. The average heart dose was 14 
Gy [9-19]. For contralateral breast, V5 was 23.6 % [0.8 to 64.9] and 
V10 was 4.4 % [0 -20]. The average dose was 4.1 Gy [2.1 -7.3]. The 
average number of monitor unit was 568 [448-772]. 
Conclusions: RapidArc treatment yielded satisfactory PTV coverage 
while ensuring sufficient organs at risk protection for treatment plans 
that would not have been acceptable with 3D-CRT.  
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Purpose/Objective: Cancer epidemiology has been extensively 
studied in developed countries. However, data addressing the 
epidemiology and the impact of the implementation of screening 
programs for breast cancer in the Middle East are scarce. We present 
a detailed epidemiological analysis of breast cancer in the Jordan 
national cancer registry with special focus on presenting the impact of 
the implementation of a nationwide screening program for breast 
cancer in 2006 in an attempt to aid the continuously evolving 
strategies for improved cancer surveillance and control. 
Materials and Methods: Data from the Jordan national cancer registry 
addressing the periods from January 1996 to December 2008 were 
meticulously reviewed. The Jordan national cancer registry which was 
established in 1996 utilizes a passive and active capture system via 
liaison personnel throughout the country.Tumor stage was classified 
into local, regional, distant or unknown. Crude incidence rates are 
expressed per 100,000 population. 
Results: Between 1996 and 2008; a total of 7,794 breast cancer cases 
were registered. Overall, 7,018 patients (89.8%) harbored ductal 
carcinoma while 478 patients (6.1%) harbored lobular carcinoma. The 
crude incidence rate of breast cancer was 20 in 1996, 21.5 in 1997, 
20.2 in 1998, 22.9 in 1999, 23.7 in2000, 23.9 in 2001, 20.5 in 2002, 
22.1 in 2003, 24.9 in 2004, 25.5 in 2005,27.5 in 2006, 29.3 in 2007 and 
29.9 in 2008. Concerning the age distribution of breast cancer cases; 
28.8% occurred in 40-49, 26.4% in 50-59, 18% in 60-69,16.6% in 30-39 
and 6.8% in 70-79 age groups. The median age was 51 years(range, 16-
100 years). Overall for breast cancer; 1,412 patients (17.4%)harbored 
local disease, 1,504 patients (19.3%) harbored regional disease, 
and1,572 patients (18.3%) harbored metastatic disease while in 3,306 
patients (45.2%)staging data was missing. For patients with known 
cancer stage, 1,954 out of a total of 2,712 patients (72.1%) presenting 
prior to 2006 and 1,047 out of a total of 1,796 patients (58.3%) 
presenting after 2006 harbored loco-regional disease.  
Conclusions: This study represents the first comprehensive 
assessment of the epidemiology of breast cancer in Jordan basing a 
framework for enhancing strategic health plans regarding cancer 
surveillance and control in Jordan and the Middle East.  
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Purpose/Objective: With this study we intended to evaluate the dose 
received by axillary levels I and II, when irradiating the breast with 
